Leerink Partnrs Has Bullish Estimate for ROIV Q2 Earnings

Key Points

• Leerink Partners has upgraded Roivant Sciences' Q2 2026 earnings forecast to ($0.31) per share, up from the previous estimate of ($0.32).
• Analysts have raised the price target for Roivant Sciences, with prices set at $22.00 from Leerink Partners and $24.00 from Goldman Sachs, reflecting a bullish outlook on the stock.
• The stock price of Roivant Sciences has opened at $15.04, with a 52-week range spanning from a low of $8.73 to a high of $16.05.

Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Leerink Partnrs increased their Q2 2026 earnings per share estimates for Roivant Sciences in a research note issued on Wednesday, September 17th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.32). The consensus estimate for Roivant Sciences' current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Roivant Sciences' FY2027 earnings at ($1.27) EPS.

A number of other research firms also recently weighed in on ROIV. Citigroup initiated coverage on shares of Roivant Sciences in a research note on Tuesday, September 2nd. They issued a "buy" rating and a $16.00 price target on the stock. HC Wainwright upped their target price on Roivant Sciences from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday. Jefferies Financial Group raised their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday. Guggenheim boosted their price target on Roivant Sciences from $15.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday. Finally, The Goldman Sachs Group raised their price objective on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $19.94.

Roivant Sciences Stock Performance

ROIV traded down $0.10 on Monday, reaching $14.94. 7,143,608 shares of the company traded hands, compared to its average volume of 8,558,282. Roivant Sciences has a 52-week low of $8.73 and a 52-week high of $16.05. The stock's 50 day moving average price is $12.28 and its 200-day moving average price is $11.32.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Matthew Gline acquired 3,315 shares of the business's stock in a transaction that occurred on Thursday, September 18th. The stock was acquired at an average price of $15.07 per share, with a total value of $49,957.05. Following the transaction, the chief executive officer owned 17,287,081 shares of the company's stock, valued at approximately $260,516,310.67. This trade represents a 0.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $11.72, for a total value of $1,172,000.00. Following the transaction, the chief executive officer directly owned 1,653,585 shares of the company's stock, valued at $19,380,016.20. This represents a 5.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,975,749 shares of company stock valued at $24,780,210 over the last quarter. Insiders own 10.80% of the company's stock.

Hedge Funds Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in the business. Valeo Financial Advisors LLC acquired a new position in shares of Roivant Sciences during the 2nd quarter worth about $1,145,000. Osaic Holdings Inc. increased its stake in Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company's stock valued at $65,000 after acquiring an additional 3,882 shares during the period. Orion Porfolio Solutions LLC acquired a new position in Roivant Sciences in the 2nd quarter valued at approximately $117,000. State of Wyoming bought a new stake in shares of Roivant Sciences in the 2nd quarter worth approximately $159,000. Finally, Headlands Technologies LLC grew its holdings in shares of Roivant Sciences by 11,882.5% during the 2nd quarter. Headlands Technologies LLC now owns 162,003 shares of the company's stock worth $1,826,000 after purchasing an additional 160,651 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.